Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1539 • ACR Convergence 2025
The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis
Muhammad Usman Hashmi¹, Paramarajan Piranavan², Yasmeen Sufi³, Zaira Nasir⁴, Zainab Azhar⁵, Shamaem Tariq⁵, Hamas Ul Hudaibia⁵, IMRAN SAEED⁶, Aayet Zulfiqar⁵, Natasha Rasool² and Anum Faiz⁷, ¹Rahmah Academy of Research Excellence, Islamabad, Pakistan., Islamabad, Pakistan, ²University of Kentucky, Louisville, KY, ³Karachi Medical & Dental College, Karachi, Karachi, Pakistan, ⁴Rawalpindi Medical University,Rawalpindi, Pakistan., Islamabad, Pakistan, ⁵Rawalpindi Medical University,Rawalpindi, Pakistan., Rawalpindi, Pakistan, ⁶Nishtar Medical University,Multan, Pakistan., Multan, Pakistan, ⁷Jinnah Hospital Lahore, Pakistan, Lahore, Pakistan
Background/Purpose: Type I interferon (IFN) signaling is central to systemic lupus erythematosus (SLE) pathogenesis, and anifrolumab, a monoclonal antibody targeting the IFN-α receptor (IFNAR), has…
Abstract Number: 1522 • ACR Convergence 2025
Outcomes of Continuing Hydroxychloroquine following Renal Transplant in Patients with Lupus Nephritis: A retrospective Cohort Study using the TrinetX database
Carlos Pena¹, Irene Tan², Rafal Ali³, Arthur Lau⁴, Shahrzad Abdollahi⁵, Fabian Rodriguez Quinonez⁶ and Marianne Meshreky⁷, ¹Jefferson Einstein Philadelphia, Wynnewood, PA, ²Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA, ³Jefferson Einstein Philadelphia, Lansdale, PA, ⁴Jefferson Einstein Hospital, Maple Glen, PA, ⁵Jefferson Einstein Hospital, Philadelphia, PA, ⁶Einstein Medical Center Philadelphia, Philadelphia, PA, ⁷St. Mary's Hospital, Philadelphia
Background/Purpose: Evidence of kidney disease occurs in up to one half of patients with SLE, and approximately 10% of the patients with lupus nephritis (LN)…
Abstract Number: 1498 • ACR Convergence 2025
Both Race and Socioeconomic Status Affect Mortality in SLE
Gursimran Kaur¹, Daniel Goldman², Andrea Fava³, Laurence Magder⁴ and Michelle Petri², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: A recent meta-analysis found an overall 2.87-fold increase in all-cause mortality in systemic lupus erythematosus (SLE) with cause-specific increases in renal disease, infections, cardiovascular…
Abstract Number: 1481 • ACR Convergence 2025
Duffy Antigen Screening in Systemic Lupus Erythematosus Patients with Neutropenia: A Quality Improvement Initiative
Divya Sudireddy¹, Jason Yang², Huseyin Berk Degirmenci³, Eva Petrow² and Michael York⁴, ¹Boston Medical Center, Westborough, MA, ²Boston Medical Center, Boston, MA, ³Boston University Medical Center, Boston, MA, ⁴Boston University, Boston, MA
Background/Purpose: Laboratory monitoring for patients with systemic lupus erythematosus (SLE) is essential for assessing disease activity and detecting treatment-related adverse effects, including cytopenias. Neutropenia in…
Abstract Number: 1301 • ACR Convergence 2025
Prevalence, Clinical and Genetic Risk Factors, and Time to Cataract Development in Childhood-onset Systemic Lupus Erythematosus
Sirikarn Tangcheewinsirikul¹, Zhaoyu Ding², Nicholas Chan³, Daniela Dominguez³, Andrea Knight⁴, Deborah Levy¹, Lawrence Ng⁵, Earl Silverman¹, Ruud Verstegen¹ and Linda Hiraki¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²SickKids Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Cataracts are a significant ocular complication in childhood-onset systemic lupus erythematosus (cSLE). This study aimed to assess the prevalence, time to cataract development, and…
Abstract Number: 1262 • ACR Convergence 2025
Perspectives of Lupus Patients on Quality of Life Measures: A Qualitative Study
Cristina Arriens¹, Fredonna Carthen², Alexandre Cammarata-Mouchtouris¹, Judith James¹, Joan Merrill³ and Motolani Ogunsanya⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Lupus has profound impact on physical, social, and emotional well-being. Health-related quality of life (HRQOL) measures are increasingly incorporated into lupus research and the…
Abstract Number: 1059 • ACR Convergence 2025
Assessing the Relationship Between Multidimensional Area Level Indicators and Lupus Disease Activity in Children
Chelsea Reynolds¹, Natasha Ruth², Paul Nietert¹, Mileka Gilbert¹, Emily Vara¹ and Joyce Chang³, ¹Medical University of South Carolina, Charleston, SC, ²Medical University South Carolina, Charleston, SC, ³Boston Children's Hospital, Boston, MA
Background/Purpose: Recent research suggests that multidimensional area-level indicators, including the Social Vulnerability Index (SVI), Area Deprivation Index (ADI) and Childhood Opportunity Index (COI), associate with…
Abstract Number: 0943 • ACR Convergence 2025
Type I and Type II IFNs have both independent and overlapping effects on SLE disease severity
Haylee Cosgrove¹, Xiaoyan Gong¹, Aidan Matunis¹ and Jeremy Tilstra², ¹University of Pittsburgh, Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The pathogenesis of systemic lupus erythematosus (SLE) is thought to be strongly influenced by the interferon (IFN) signaling pathway, particularly type I IFNs (IFNα/β).…
Abstract Number: 0902 • ACR Convergence 2025
A Novel Approach to study ANA+ B Cells in Lupus Integrating Flow Cytometry with Single-Cell culture
Deisy Muriel Velez arteaga¹, Yemil Atisha Fregoso², Hasret Gunduz³ and Betty Diamond⁴, ¹The Elmezzi School of Molecular Medicine, New Rochelle, NY, ²The Feinstein Institute, Long Island, NY, ³The Feinstein Institute, Long Island, ⁴The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Studying antinuclear antibody (ANA) producing B cells at the single-cell level offers critical insights into their fine specificity and functional characteristics. However, conventional techniques…
Abstract Number: 0648 • ACR Convergence 2025
Real World Comparative Use of Anifrolumab in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A Multicenter Cohort Study
Rajaie Namas¹, Sarah Al Qassimi², Rowaida Abdou³, Jawahir Alameri², Reem Alblooshi⁴, Fatima Abdulla⁴, Muriel Ghosn⁴, Amir Malik⁴, Raghda Almaashari⁴, Fulvio Salvo⁴, Mohamed Abuzakouk⁴, Atheer Al Ansari⁵, Hazem Helmy Ali Rifaai⁵, Ahlam Almarzooqi⁶, Asia Mubashir⁷, Ahmed Aldhaheri⁴, Suzan Attar⁸ and Mohamed Elarabi⁹, ¹Cleveland Clinic Abu Dhabi, Detroit, MI, ²Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ³NMC Specialty Hospital Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁴Cleveland Clinic Abu Dhabi, Abu Dhabi, ⁵Mediclinic, Abu Dhabi, United Arab Emirates, ⁶Emirates Health Services, Sharjah, United Arab Emirates, ⁷Cleveland Clinic, Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁸King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia, ⁹Cleveland Clinic Abu Dhabi, Hannon, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiorgan organ damage, and early mortality. Anifrolumab (ANI), a human monoclonal antibody targeting the…
Abstract Number: 0630 • ACR Convergence 2025
Development, Validation and Performance of a Patient Knowledge Assessment Tool for Assessing the Immediate and Short-term Impact of an Information Course in Systemic Lupus Erythematosus
Ranjan Gupta, Rudra Prosad Goswami and Anju Mohan, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Long-term outcomes in rheumatic diseases can be improved by improving patients’ knowledge, beliefs and perception about their disease. However, there is a lack of…
Abstract Number: 0611 • ACR Convergence 2025
Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study
Fadi Kharouf¹, Pankti Mehta², Qixuan Li², Dafna D. Gladman³, Laura Whitall Garcia⁴ and Zahi Touma⁵, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Venous thromboembolism (VTE) is a known complication of systemic lupus erythematosus (SLE), yet there is a lack of high-quality studies specifically focused on lupus…
Abstract Number: 0595 • ACR Convergence 2025
Sustained Remission In SLE Is Infrequent On Standard Of Care: A Decade Of Insights From The Asia Pacific Lupus Collaboration
Rangi Kandane-Rathnayake¹, Yi-Hsing Chen², Alberta Hoi³, Vera Golder⁴, Worawit Louthrenoo⁵, Jiacai Cho⁶, Aisha Lateef⁷, Laniyati Hamijoyo⁸, Shue Fen Luo⁹, Yeong-Jian Jan Wu¹⁰, Chiu Wai Shirley Chan¹¹, Leonid Zamora¹², Yasuhiro Katsumata¹³, Sargunan Sockalingam¹⁴, Zhanguo Li¹⁵, Haihong Yao¹⁵, BMDB Basnayake¹⁶, Yih Jia Poh¹⁷, Yanjie Hao¹⁸, Zhuoli Zhang¹⁹, Madelynn Chan²⁰, Jun Kikuchi²¹, Yuko Kaneko²², Tsutomu Takeuchi²³, Shereen Oon²⁴, Kristine Ng²⁵, Sang-Cheol Bae²⁶, Cherica Tee²⁷, Michael Tee²⁷, Nicola Tugnet²⁸, Sean O’Neill²⁹, Geraldine Hassett³⁰, Fiona Goldblatt³¹, Naoaki Ohkubo³², Yusuke Miyazaki³², Mark Sapsford³³, Yoshiya Tanaka³⁴, Sandra Navarra³⁵, Chak Sing Lau³⁶, Mandana Nikpour³⁷ and Eric Morand³⁸, ¹Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, ²Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Taichung, Taiwan (Republic of China), ³Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, ⁴Monash University, Clayton, Australia, ⁵Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, Chiang Mai, Thailand, ⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, Singapore, Singapore, ⁷Woodlands Health, Singapore, Singapore, ⁸Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, Badung, Indonesia, ⁹Chang Gung Memorial Hospital, Chang Gung University, Department of Rheumatology, Allergy and Immunology, Taipei, Taiwan, Taoyuan, Taiwan (Republic of China), ¹⁰Chang Gung Memorial Hospital, Chang Gung University, Taoyuan City, Taiwan (Republic of China), ¹¹Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ¹²University of Santo Tomas Hospital, Manila, Philippines, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴University of Malaya Medical Center, Kuala Lumpur, Malaysia, ¹⁵Peking University People's Hospital, Beijing, China (People's Republic), ¹⁶National Hospital Kandy, Kandy, Sri Lanka, ¹⁷Singapore General Hospital, Singapore, Singapore, ¹⁸St Vincent’s Hospital Melbourne, Fitzroy, Australia, ¹⁹Peking University First Hospital, Beijing, Beijing, China (People's Republic), ²⁰Tan Tock Seng Hospital, Singapore, Singapore, ²¹Keio University, Tokyo, Japan, ²²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²³Saitama Medical University and Keio University, Tokyo, Japan, ²⁴St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia, ²⁵Health New Zealand Waitemata, Te Whatu Ora, Auckland, New Zealand, ²⁶Hanyang University Medical Center, Seoul, South Korea, ²⁷University of the Philippines, Manila, Philippines, ²⁸Health New Zealand Auckland, Te Whatu Ora (Auckland District Health Board), Auckland, New Zealand, ²⁹The University of Sydney, Sydney, Australia, ³⁰Liverpool Hospital, NSW, Liverpool, Australia, ³¹Flinders Medical Centre, Bedford park, Australia, ³²University of Occupational and Environmental Health, Kitakyushu, Japan, ³³Health New Zealand Counties Manukau, Te Whatu Ora (Middlemore Hospital),, Auckland, New Zealand, ³⁴University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³⁵University of Santo Tomas, Manila, Philippines, ³⁶The University of Hong Kong, Hong Kong, Hong Kong, ³⁷University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia, ³⁸Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia
Background/Purpose: Treat-to-target (T2T) states in SLE, such as the Lupus Low Disease Activity State (LLDAS) and remission (REM) as defined by the Definitions of Remission…
Abstract Number: 0801 • ACR Convergence 2025
Achieving Sustained Lupus Low Disease Activity State and Remission With Ianalumab (VAY736) in Patients with Systemic Lupus Erythematosus: A post hoc Analysis From a Phase II Study
Eric Morand¹, Corine Gaillez², Stephen Oliver³, Swati Ghanshani⁴, Marilia Pozzobon⁵, Weibin Bao⁶ and Ed Vital⁷, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²Novartis Pharma AG, Basel, Switzerland, Croissy Sur Seine, France, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Healthcare Private Limited, Hyderabad, India, Hyderabad, India, ⁵Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, Hanover, NJ, ⁷University of Leeds, Leeds, England, United Kingdom
Background/Purpose: Ianalumab, a fully human monoclonal antibody against the B cell–activating factor receptor (BAFF-R), has a dual mechanism of action of B cell depletion through…
Abstract Number: 0217 • ACR Convergence 2025
Development of the American College of Rheumatology Implementation Guide for Integrating Patient Reported Systemic Lupus Erythematosus Quality Measures
Catherine Nasrallah¹, Christine Hariz², Shanthini Kasturi³, Wambui Machua⁴, Jinoos Yazdany⁵, Christie Bartels⁶, Kate Chiseri⁷, Starla Blanks⁷, Patti Katz⁸, Cherish Wilson⁹, April Jorge¹⁰, Beth Radtke¹¹, Tom Tack⁷ and Shivani Garg¹², ¹University of California San Francisco (UCSF), San Francisco, CA, ²University of California San Francisco (UCSF, San Francisco, CA, ³Tufts Medical Center, Boston, MA, ⁴Piedmont Healthcare, Atlanta, GA, ⁵UCSF, San Francisco, CA, ⁶University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷American College of Rheumatology, Atlanta, GA, ⁸UCSF, San Rafael, CA, ⁹UCSF / SFVA, San Francisco, CA, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹ACR, Atlanta, GA, ¹²University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex disease that presents unique care challenges. To improve high-quality patient-centered care, the American College of Rheumatology (ACR),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].